Cardiometabolic RNA and next-generation lipid drug trial starts vs Gene editing trial starts
In 2025, cardiometabolic RNA and next-generation lipid drug trial starts worldwide stood at 30, against 35 for gene editing trial starts.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Cardiometabolic RNA and next-generation lipid drug trial starts and Gene editing trial starts
Unit: count · 12 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Cardiometabolic RNA and next-generation lipid drug trial starts | 2025 | Actual | 30 |
| Cardiometabolic RNA and next-generation lipid drug trial starts | 2024 | Actual | 51 |
| Cardiometabolic RNA and next-generation lipid drug trial starts | 2023 | Actual | 22 |
| Cardiometabolic RNA and next-generation lipid drug trial starts | 2022 | Actual | 32 |
| Cardiometabolic RNA and next-generation lipid drug trial starts | 2021 | Actual | 28 |
| Cardiometabolic RNA and next-generation lipid drug trial starts | 2020 | Actual | 6 |
| Gene editing trial starts | 2025 | Actual | 35 |
| Gene editing trial starts | 2024 | Actual | 40 |
| Gene editing trial starts | 2023 | Actual | 27 |
| Gene editing trial starts | 2022 | Actual | 23 |
| Gene editing trial starts | 2021 | Actual | 17 |
| Gene editing trial starts | 2020 | Actual | 14 |
Shared periods
Side by side
6 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.
| Period | Cardiometabolic RNA and next-generation lipid drug trial starts | Gene editing trial starts |
|---|---|---|
| 2020 | 6 ClinicalTrials.gov | 14 ClinicalTrials.gov |
| 2021 | 28 ClinicalTrials.gov | 17 ClinicalTrials.gov |
| 2022 | 32 ClinicalTrials.gov | 23 ClinicalTrials.gov |
| 2023 | 22 ClinicalTrials.gov | 27 ClinicalTrials.gov |
| 2024 | 51 ClinicalTrials.gov | 40 ClinicalTrials.gov |
| 2025 | 30 ClinicalTrials.gov | 35 ClinicalTrials.gov |
Provenance
Where these numbers come from
Cardiometabolic RNA and next-generation lipid drug trial starts
Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Gene editing trial starts
Count of interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring